ALKERMES | ALKS - Ebitda


ALKERMES reported $80.26M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
AbbVie USD 5.37B 1.85B Dec/2025
Acadia Pharmaceuticals USD 20.31M 15.44M Dec/2025
ALKERMES USD 80.26M 20.05M Mar/2026
Amgen USD 5.14B 775M Dec/2025
Biogen USD 649.7M 76.5M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Coherus Biosciences USD -43.33M 4.7M Sep/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
Gilead Sciences USD 3.02B 1.01B Dec/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Ionis Pharmaceuticals USD -200.02M 42.89M Dec/2025
J&J USD 8.27B 1.08B Mar/2026
Malin Corporation EUR -1.1M 200K Dec/2024
Merck USD 6.3B 2.09B Dec/2025
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Nektar Therapeutics USD -31.81M 70K Sep/2023
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Otsuka Holdings JPY 156.66B 56.89B Mar/2026
Pfizer USD 5.99B 5.23B Mar/2026
Regeneron Pharmaceuticals USD 1.2B 718.4M Dec/2025
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026